DIRS.INFO The most relevant business & tech news

☆ Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says
▼ + stars: | 2024-04-17 | by ( Jen Christensen | ) edition.cnn.com time to read: +4 min

CNN —Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday. Based on results from trials in people with sleep apnea, the company said it plans to submit the material to the US Food and Drug Administration to potentially expand the use of Zepbound for obstructive sleep apnea. Obstructive sleep apnea is a disorder that causes people to briefly stop breathing while they are sleeping, sometimes several times an hour. While people are more at risk for obstructive sleep apnea as they get older, it often develops when people gain weight and have overweight or obesity. Some doctors have been prescribing the weekly injection off label to people with obstructive sleep apnea, and Lilly has been testing the drug for obstructive sleep apnea since June 2022.

Persons: CNN —, Eli Lilly, Lilly, didn’t, Dr, Sanjay Gupta, CNN’s Meg Tirrell, Amanda Sealy Organizations: CNN, Food and Drug Administration, World Health, US Food and Drug Administration, CNN Health, American Diabetes Association

☆ Another perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too
▼ + stars: | 2024-04-17 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +4 min

GLP-1 drugs were originally developed to treat type 2 diabetes. Drugmakers are discovering the injections may also aid weight loss, heart issues, and sleep apnea. AdvertisementAnother new indication for injectable GLP-1 drugs: better sleep. On Wednesday, drugmaker Eli Lilly announced positive results from a large, phase-3 clinical trial, testing Zepbound (the drug name for tirzepatide) as a treatment for sleep apnea. Related storyAlready, GLP-1 drugs have been indicated for the treatment of:ObesityHeart diseaseAdvertisementIn clinical trials, GLP-1 drugs have also shown some promise for treating other conditions, including:Non-alcoholic fatty liver diseaseAddictionDepressionParkinson's and Alzheimer'sCancerThese breakthroughs may be tied to the gut-brain connectionScientists think that the main reason GLP-1 drugs work well is because of their effect on our body's gut-brain connection.

Persons: —, drugmaker Eli Lilly, Eli Lilly, KATERYNA, Daniel Drucker, GLP, Eric Topol Organizations: Service, Food and Drug Administration, American Diabetes Association, University of Toronto

☆ Stocks give up early gains — Here's why a busy week of earnings is good news for investors
▼ + stars: | 2024-04-15 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. There is nothing markets hate more than uncertainty, which is why stocks struggled to hold onto their early gains. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Morgan Stanley, Goldman Sachs, Charles Schwab bode, Eli Lilly, It's, Jim Cramer's, Jim Organizations: CNBC, Dow Jones, Abbott Laboratories, Jim Cramer's Charitable Locations: East

☆ Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7
▼ + stars: | 2024-03-08 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

In today's big story, we're looking at pharma companies' surging stocks and threatening tech darlings thanks to their weight-loss drugs. And it comes despite only 1% of US adults taking weight-loss drugs, according to Bank of America , which predicts that number could rise to 15% by 2035. Weight-loss drugs are also cutting more than just fat. For Wall Street, meanwhile, the equation is much simpler: Getting more people on weight-loss drugs boosts the economy. The trend, which will be powered by cash-rich mega-cap tech companies, is thanks to strong earnings growth, the bank said.

Persons: —, Joe Biden, Donald Trump —, Trump, Zhan, Eli Lilly, Tesla, Hannah Latham, Octavio Jones, Christian Rodriguez, Laura MacPherson, Jenny Chang, Rodriguez, they're, Goldman Sachs, Biden, Barry Sternlicht, Fernando Gutierrez, It's, Elon Musk, TikTok, Pete Ryan, RJ Scaringe, Dan DeFrancesco, Hallam Bullock, Jordan Parker Erb, George Glover Organizations: Service, pharma, Business, Tesla, Microsoft, JPMorgan, Pfizer, Novo Nordisk, Bank of America, Nvidia, Companies, Fed, Infrastructure Investment, Alpha, Commission, Elon, EV, Nike, Congress, White, Meta, SXSW Locations: China, US, New York, London

☆ A rare downgrade of a portfolio stock that's consistently beaten the market is way off base
▼ + stars: | 2024-01-22 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. The S & P 500 started the new week building on Friday's record high. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Dow, Jim, Tesla, Eli Lilly, Lilly, Linde, Stifel, Jim Cramer's Organizations: CNBC, Nasdaq, Apple, Microsoft, Nvidia, Jim Cramer's Charitable

☆ How every Club stock performed over the past 10 Decembers, a historically strong month
▼ + stars: | 2023-12-05 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +6 min

After closing at its highest level of 2023 on Friday , the first day of December, the S & P 500 fell Monday. A mixed picture is revealed when looking at how every Club stock has performed in December over the past decade. The best-performing Club stock over the past 10 Decembers is Broadcom (AVGO), which has an average gain of 7.1% in the month. Salesforce (CRM) is the worst-performing Club stock in December over the past decade, falling 4.53% on average in the month. Amazon (AMZN), Coterra Energy (CTRA) and Costco (COST) round out the bottom five December performers over the past decade.

Persons: Sam Stovall, Santa Claus, hasn't, It's, Thursday's, Estee Lauder, Eli Lilly, —, Jim Cramer's, Jim Cramer, Jim, Tayfun Organizations: GE Healthcare, Broadcom, Procter & Gamble, Wynn Resorts, WYNN, Salesforce, Ford, Palo Alto Networks, Coterra Energy, Costco, Amazon, Caterpillar, Jim Cramer's Charitable, CNBC, Wall, York Stock Exchange, Financial, Anadolu Agency, Getty Locations: Santa, Broad St, New York City, United States

☆ CNBC Daily Open: Oil deals ahead of Big Tech earnings
▼ + stars: | 2023-10-24 | by ( Shreyashi Sanyal | ) www.cnbc.com time to read: +2 min

In this article GOOGL Follow your favorite stocks CREATE FREE ACCOUNTOmar Marques | Lightrocket | Getty ImagesThis report is from today's CNBC Daily Open, our new, international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Unlike more focused software companies, Microsoft "has full geographic coverage across all industry verticals," UBS analyst Karl Keirstead said, and that makes Microsoft less susceptible to downturns in any one sector or region. Most analysts predict the sales of weight loss drugs such as Wegovy and Mounjaro could easily exceed $100 billion. Still, that's conservative compared to Guggenheim's expectations of $150 billion to $200 billion in sales.

Persons: Omar Marques, Hess, Canaccord, Tony Dwyer, Karl Keirstead, Mounjaro, drugmaker Eli Lilly Organizations: Lightrocket, CNBC, Big Tech, Nasdaq, Chevron, Exxon Mobil, Stocks, Microsoft, UBS, Wall Street, Citi, Novo Nordisk Locations: .

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 11, 2023. U.S. producer prices increased more than expected in September amid higher costs for energy products, but underlying inflation pressures at the factory gate continued to moderate. Yield on the benchmark 10-year notes fell to a roughly two-week low as prices rose on safe-haven flows due to fighting in the Middle East that has persisted for a fifth straight day. Advancing issues outnumbered decliners for a 1.51-to-1 ratio on the NYSE, while declining issues outnumbered advancers for a 1.10-to-1 ratio on the Nasdaq. The S&P index recorded 11 new 52-week highs and seven new lows, while the Nasdaq recorded 38 new highs and 124 new lows.

Persons: Brendan McDermid, Fed's Bowman, Raphael Olszyna, J Safra, Michelle Bowman, Christopher Waller, Birkenstock, Tim Wentworth, Drugmaker Eli Lilly, LLY.N, Novo, decliners, advancers, Shashwat Chauhan, Ankika Biswas, Arun Koyyur, Shounak Organizations: New York Stock Exchange, REUTERS, Fed's Bowman Exxon, Nasdaq, Treasury, Federal, Apple, Microsoft, Nvidia, Fed, Energy, Exxon Mobil, Natural Resources, Dow Jones, Walgreens Boots Alliance, Novo Nordisk's, Baxter International, NYSE, Thomson Locations: New York City, U.S, Middle East, Israel, Gaza, Bengaluru

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 11, 2023. ET is expected to show the producer price index for final demand increased 0.3% last month after a 0.7% rise in August, ahead of Thursday's closely watched consumer inflation data. Yields on government bonds have eased from their multi-year highs on dovish remarks from Fed officials earlier this week. Central bank officials such as Fed Governor Christopher Waller, Atlanta Fed President Raphael Bostic and Boston Fed President Susan Collins are also scheduled to speak on Wednesday. Exxon Mobil (XOM.N) lost 1.7% as the oil and gas producer is set to buy shale producer Pioneer Natural Resources (PXD.N) in an all-stock deal valued at $59.5 billion.

Persons: Brendan McDermid, Fed's Bowman, Michelle Bowman, Christopher Waller, Raphael Bostic, Susan Collins, Mark Haefele, Birkenstock, Tim Wentworth, Piper Sandler, Drugmaker Eli Lilly, LLY.N, Novo, Shashwat Chauhan, Ankika Biswas, Arun Koyyur, Shounak Organizations: New York Stock Exchange, REUTERS, Companies, Fed's Bowman Exxon, Futures, Dow, Nasdaq, Treasury, Federal, Labor Department, Atlanta Fed, Boston Fed, UBS Global Wealth Management, Traders, Microsoft, Nvidia, Palestinian, Hamas, Dow e, Walgreens Boots Alliance, Arista Networks, Exxon Mobil, Natural Resources, Novo Nordisk's, Baxter International, Thomson Locations: New York City, U.S, Gaza, Thursday's, Middle East, Israel, Bengaluru

☆ Cramer tells market skeptics to focus on solid companies, not day-to-day action
▼ + stars: | 2023-08-08 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Tuesday advised investors to focus on finding companies with solid products and long-term potential when trading in the stock market. According to Cramer, day-to-day stock movements can be confusing and sometimes hold little weight. "Put simply, most people don't trust the market anymore. They don't trust CEOs. They don't trust individual companies.

Persons: CNBC's Jim Cramer, Cramer, he's, Eli Lilly, Mounjaro Organizations: Nvidia

☆ Cramer says keep it simple and wait for prices to drop
▼ + stars: | 2023-07-24 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer preached a straightforward message on Monday: Keep it simple, stupid. Cramer urged investors to bide their time and wait for a swoon in a company's price before buying. Cramer also highlighted beverage and food giant PepsiCo , along with travel and leisure front-runners, Boeing and American Express . "I think this is a matter of keeping it simple, stupid," Cramer said. But if a company is not overbought, Cramer urged investors to wait for a swoon after a company's earnings report, or a market-wide dip.

Persons: CNBC's Jim Cramer, Cramer, Eli Lilly, I've, Tesla Organizations: Nvidia, Microsoft, Nasdaq, Adobe, Caterpillar, PepsiCo, Boeing, American Express, Wall, Netflix

"Twitter Blue is a mess. Within the next 48 hours, all but 110 of the most-followed Twitter accounts suddenly had verification through Twitter Blue, indicating Twitter likely gifted the check marks, independent researcher Travis Brown told Reuters. GRADUAL PULLBACKSince the initial rollout of the Twitter Blue service in November, imposter tweets have spread harmful misinformation. Imposter Twitter accounts also tarnished the online reputations of Lockheed Martin Corp(LMT.N) and Nintendo Co Ltd(7974.T). "The volume of imposter accounts seems to depend on several things -- Is the client doing a high profile event that week?

Bischoff died on Tuesday of natural causes, a close relative, who asked not to be named, told Reuters on Wednesday. A former chairman of Lloyds Banking Group (LLOY.L), Citigroup (C.N) and more recently JP Morgan Securities (JPM.N), Bischoff had also been CEO of Schroders (SDR.L). Robert Swannell, former chairman of Marks & Spencer, who worked with Bischoff for 33 years at Schroders and later Citi, said he would profoundly mourn his friend and colleague. The deal was hailed as a huge success for Bischoff's leadership team, having started with a business worth just a fraction of the 1.3 billion pounds price Citi later paid. He returned to JP Morgan as chairman of JP Morgan Securities the same year.

☆ Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli Lilly
▼ + stars: | 2023-03-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Novo Nordisk Inc. NovoLog brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Novo Nordisk, one of the world's biggest insulin makers, will cut the list price of its NovoLog insulin by 75% and the prices for Levemir and Novolin by 65%, the company said in a press release. NovoLog's list price will fall to $139.71 from $558.83 for a pack of five injection pens. The company also said it plans to reduce the list price of its unbranded insulin products to match the lowered price of each respective branded insulin. Novo Nordisk, Lilly and Sanofi control over 90% of the global insulin market.

☆ Biden budget would cap monthly insulin prices at $35 for people with private insurance
▼ + stars: | 2023-03-09 | by ( Spencer Kimball | ) www.cnbc.com time to read: +1 min

President Joe Biden's federal budget proposal would cap insulin prices at $35 per month for people with private insurance plans. Biden called on Congress in his State of the Union speech to finish the job and cap insulin at $35 a month for everybody. Drugmaker Eli Lilly got ahead of a potential federal mandate, announcing earlier this month that it would cap insulin at $35 per month for people with private insurance at certain retail pharmacies. About 40% of people with diabetes have private insurance while 5% are not insured, according to the American Diabetes Association. Some Republicans in Congress oppose to the move to cap insulin prices.

☆ Jim Cramer's Investing Club meeting Monday: Fed and jobs, China reopening, Eli Lilly
▼ + stars: | 2023-03-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Fed and jobs report Stocks were trading higher Monday as investors look ahead to Federal Reserve commentary and new economic data later this week. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance
▼ + stars: | 2023-03-01 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

The Inflation Reduction Act capped insulin prices for Medicare beneficiaries at $35 per month but did not protect people with private insurance or who don't have coverage from higher prices. In President Joe Biden's State of the Union speech, he called on Congress to cap insulin prices at $35 a month for everyone. Lilly said it will cap out-of-pocket costs at $35 per month effectively immediately at certain retail pharmacies for people with private insurance. One in five people with diabetes who have private insurance pay more than $35 per month for insulin, according to the Kaiser Family Foundation. Democrats in Congress had pushed to cap insulin at $35 per month last summer for people with private insurance, but Senate Republicans killed the measure.

☆ Here’s our third-quarter earnings report card for all the stocks in our portfolio
▼ + stars: | 2022-12-27 | by ( Zev Fima | ) www.cnbc.com time to read: +17 min

Third-quarter earnings season is finally behind us — and like the prior quarter, results were solid overall compared to analyst forecasts. Danaher (DHR) reported sales and earnings beats on the back of better-than-expected results in all three segments of the health technology company. While U.S. customer traffic was down in the quarter, management noted that it improved sequentially and improved throughout the quarter. Still the luxury hotel and casino company reported solid third-quarter results boosted by its U.S. properties. Amazon (AMZN) reported results that were disappointing, to say the least, and compounded by guidance that was even worse.

☆ How we're thinking about our Club stock exposure to China following Covid protests
▼ + stars: | 2022-11-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Global stocks slumped Monday on growing concerns about intensifying protests across China over the communist government's strict Covid policies. Apple (AAPL) — Revenue from China : 17.7% (China is the iPhone maker's second-largest market, lagging just the U.S. at 37.5% of sales.) Disney (DIS) — Revenue from China: 4.8% Devon Energy (DVN) — Revenue from China: 0% Estee Lauder (EL) — Revenue from China: 29.7% (China is the cosmetic giant's largest sales market, followed by the U.S. at 19.8%, per FactSet.) Ford Motor (F) — Revenue from China: 4.6% Alphabet (GOOGL) — Revenue from China: 3.8% Halliburton (HAL) — Revenue from China: 1.6% Honeywell International (HON) — Revenue from China: 4.2% Humana (HUM) — Revenue from China: 0% Johnson & Johnson (JNJ) — Revenue from China: 3.1% Eli Lilly (LLY) — Revenue from China: 5.7% Linde (LIN) — Revenue from China: 8.1% Meta Platforms (META): Revenue from China: 2.6% Morgan Stanley (MS) — Revenue from China: 2.6% Microsoft (MSFT) — Revenue from China: 12.4% Nvidia (NVDA) — Revenue from China: 25.8% — keep in mind: Nvidia's revenue is not attributed to the country in which the consumer buys a product that contains one of the company's semiconductors. Procter & Gamble (PG) — Revenue from China: 13.7% (China is P & G's second-largest sales market, with the U.S. accounting for 45.5% of revenue).

☆ Musk halts Twitter's coveted blue check amid proliferation of imposters
▼ + stars: | 2022-11-12 | by ( Nivedita Balu | ) www.reuters.com time to read: +3 min

The coveted blue check mark was previously reserved for verified accounts of politicians, famous personalities, journalists and other public figures. The flip-flop is part of a chaotic two weeks at Twitter since Musk completed his $44 billion acquisition. Musk has fired nearly half of Twitter's workforce, removed its board and senior executives, and raised the prospect of Twitter's bankruptcy. A number of misleading tweets about Tesla from a verified account with the same profile picture as the company's official account were also being circulated on the platform. In response, the billionaire said on Wednesday he aimed to turn Twitter into a force for truth and stop fake accounts.

☆ Eli Lilly to buy genetic medicine developer Akouos for $487 million
▼ + stars: | 2022-10-18 | by ( Shashwat Awasthi | Byron Kaye | ) www.reuters.com time to read: 1 min

Oct 18 (Reuters) - Drugmaker Eli Lilly and Co (LLY.N) will acquire genetic medicine developer Akouos Inc (AKUS.O) in a cash deal worth about $487 million. Lilly will also pay Akouos' shareholders an additional amount of about $610 million contingent on certain events related to its trials. Register now for FREE unlimited access to Reuters.com RegisterReporting by Leroy Leo in Bengaluru; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "Drugmaker Eli Lilly"

21 mentions found